

:

2024 Summer Institute In Statistics for Clinical & Epidemiological Research

Module 3:

Design, Conduct, and Analysis of Randomized Clinical Trials with Time to Event Primary Endpoints

.....

Lecture 21:
RCTdesign

Scott S. Emerson, M.D., Ph.D.
Professor Emeritus of Biostatistics
University of Washington

1

RCTdesign: Raison d'Être

.....

- Software for design, conduct, and analysis of sequential clinical trials
 - A broad spectrum of group sequential designs
 - A full complement of tools for evaluation of operating characteristics
 - Seamless progression from design to monitoring to analysis
- Extensible, object-oriented language to facilitate
 - Exploration of alternative designs to address needs of individual trials
 - Research into development of new clinical trial methodology

2

2

:

Clinical Trial Design

.....

- Finding an approach that best addresses the often competing goals: Science, Ethics, Efficiency
 - Basic scientists: focus on mechanisms
 - Clinical scientists: focus on overall patient health
 - Ethical: focus on patients on trial, future patients
 - Economic: focus on profits and/or costs
 - Governmental: focus on safety of public: treatment safety, efficacy, marketing claims
 - Statistical: focus on questions answered precisely
 - Operational: focus on feasibility of mounting trial

3

3

Classical Fixed Sample Designs

.....

- Design stage:
 - Choose a sample size

- Conduct stage:
 - Recruit subjects, gather all the data

- Analysis stage:
 - When all data available, analyze and report

4

4

:

Group Sequential Designs

- Design stage:
 - Choose an interim monitoring plan
 - Choose a maximal stopping time
 - Statistical information, sample size, calendar time
- Conduct stage:
 - Recruit subjects, gather data in groups
 - After each group, analyze for DMC
 - DMC recommends termination or continuation
- Analysis stage:
 - When study stops, analyze and report

5

5

Group Sequential Approach

- Perform analyses when sample sizes N_1, \dots, N_J
 - Can be randomly determined if independent of effect
- At each analysis choose stopping boundaries
 - $a_j < b_j < c_j < d_j$
- Compute test statistic $T_j = T(X_1, \dots, X_{N_j})$
 - Stop if $T_j < a_j$ (extremely low)
 - Stop if $b_j < T_j < c_j$ (approximate equivalence)
 - Stop if $T_j > d_j$ (extremely high)
 - Otherwise continue

6

6

:

Distinctions without Differences



- Sequential sampling plans
 - Group sequential stopping rules
 - Error spending functions
 - Conditional / predictive power
 - Bayesian posterior probabilities
- Statistical treatment of hypotheses
 - Superiority / Inferiority / Futility
 - Two-sided tests / bioequivalence

7

7

Evaluation of Designs



- Define candidate design constraining two operating characteristics
 - Type I error, power at design alternative
 - Type I error, maximal sample size
- Evaluate other operating characteristics
 - Sample size requirements
 - Power curve
 - Inference to be reported upon termination
 - (Probability of a reversed decision)
- Modify design
- Iterate

8

8

:

But What If ...?

- Possible motivations for adaptive designs
 - Changing conditions in medical environment
 - Approval / withdrawal of competing / ancillary treatments
 - Diagnostic procedures
 - New knowledge from other trials about similar treatments
 - Evidence from ongoing trial
 - Toxicity profile (therapeutic index)
 - Interim estimates of primary efficacy / effectiveness endpoint
 - Overall
 - Within subgroups
 - Interim alternative analyses of primary endpoints
 - Interim estimates of secondary efficacy / effectiveness endpoints

9

9

Adaptive Sampling Plans

- At each interim analysis, possibly modify statistical or scientific aspects of the RCT
- Primarily statistical characteristics
 - Maximal statistical information (UNLESS: impact on MCID)
 - Schedule of analyses (UNLESS: time-varying effects)
 - Conditions for stopping (UNLESS: time-varying effects)
 - Randomization ratios
 - Statistical criteria for credible evidence
- Primarily scientific characteristics
 - Target patient population (inclusion, exclusion criteria)
 - Treatment (dose, administration, frequency, duration)
 - Clinical outcome and/or statistical summary measure

10

10

:

Adaptive Sample Size Approach



- Perform analyses when sample sizes N_1, \dots, N_J
 - N_1, \dots, N_{J-1} can be randomly determined indep of effect

- At each analysis choose stopping boundaries
 - $a_j < b_j < c_j < d_j$

- At N_1, \dots, N_{J-1} compute test statistic $T_j = T(X_1, \dots, X_{N_j})$
 - Stop if $T_j < a_j$ (extremely low)
 - Stop if $b_j < T_j < c_j$ (approximate equivalence)
 - Stop if $T_j > d_j$ (extremely high)
 - Otherwise continue
 - At N_{j-1} determine N_j according to value of T_j

11

11

Implementation in R



12

:

Actual Use

- We use RCTdesign to narrow the search for useful group sequential designs
 - Typically specify type I error and
 - Design alternative and desired power OR
 - Design alternative and maximal sample size OR
 - Maximal sample size and desired power
 - Search through a family of stopping boundaries
 - Alternative criteria for early stopping: null, alternative, both
 - Alternative degrees of “early conservatism”
 - Alternative number and schedule of analyses
- We use RCTdesign to evaluate operating characteristics
 - Different operating characteristics of interest to different collaborating disciplines

13

13

Implementation in R: Basic Objects

- seqModel
 - Probability model for primary endpoint
 - Statistical analysis model
- seqBoundary
 - A stopping rule (on some scale)
- seqOperatingChar
 - Stopping probabilities
 - Power (including type I error)
 - Sample size distribution
- seqInference
 - Point estimates, confidence intervals, P values

14

14

:

Implementation in R: Basic Objects (Survival)



- seqPHAccrual
 - Describes parameters for subject accrual
 - Number of subjects accrued
 - Administrative censoring: Distribution of entry times
 - Potentially informative censoring: Distribution of dropout times
 - Additional follow-up time
- seqPHNSubjects
 - Summarizes number of subjects accrued and at risk

15

15

Implementation in R: High Level Objects



- seqDesign
 - Probability model for primary endpoint
 - Statistical hypotheses
 - Design parameters to specify a boundary
 - Stopping boundaries
 - Survival: Accrual and risk set information
- seqMonitor
 - A group sequential design
 - Interim data
 - Updated monitoring boundaries
 - Statistical inference

16

16

:

Implementation in R: Operations

- Creation of objects
 - User interface to facilitate scientific interpretations
 - (Graphical user interface (GUI) under development)
- Printing objects
 - Information necessary for protocols, statistical analysis plans
- Plotting objects
 - Facilitate comparisons among candidate designs
- Updates of objects

17

17

Basics: Probability Model

- The primary clinical outcome of a RCT is summarized by θ
- Common choices for θ in two arm studies
 - Difference (or ratio) of means
 - Ratio of geometric means
 - Difference (or ratio) of proportions having some event
 - Ratio of odds of having some event
 - Ratio (or difference) or rates of some event
 - Ratio of hazards (time averaged?)
- Note that all of the above can be analyzed in (nearly) a distribution-free manner
 - Sums used in the statistics mean that CLT provides good approximation

18

18

:

Stopping Boundary Scales

- Boundary scales (1:1 transformations among these)
 - Z statistic
 - P value
 - Fixed sample (so wrong)
 - Computed under sequential sampling rule (so correct)
 - Error spending function
 - Estimates
 - MLE (biased due to stopping rule)
 - Adjusted for stopping rule
 - Conditional power
 - Computed under design alternative or arbitrary choice
 - Computed under current MLE
 - Predictive power
 - Computed under flat prior (possibly improper) or arbitrary normal prior

19

19

Basics: Defining a Scale

- seqScale (
 - scaleType : a code for which boundary scale
("S", "X", "Z", "P", "E", "C", "H")
 - threshold : optional argument used for some scales
 - hypTheta : optional argument used for some scales
 - priorTheta : optional argument used for some scales
 - priorVariation : optional argument used for some scales
 - pessimism : optional argument used for some scales
 - boundaryNumber : optional argument used for some scales
 - scaleParameters : optional argument used for some scales

20

20

:

Basics: Creating a Stopping Boundary



- `seqBoundary` (
 - `x` : a J by 4 matrix of stopping thresholds
 - `scale` : (a code for) which boundary scale
 - `sample.size` : a J vector of sample sizes at analysis times
 - `no.stopping` : optional argument used for display
 - ... : additional arguments to define boundary scales

21

21

Basics: Creating a RCT Design (partial)



- `seqDesign` (
 - `prob.model` : probability model for primary endpoint
 - `arms` : number of arms (1,2,... or 0 for regression)
 - `null.hypothesis` : a vector (length corresponds to arms)
 - `alt.hypothesis` : a vector (length corresponds to arms)
 - `variance` : a vector (length corresponds to arms)
 - `ratio` : a vector (length corresponds to arms)
 - `sample.size` : a vector of sample sizes at analysis times
 - `test.type` : "greater", "less", "two.sided"
 - `exact.constraint` : a stopping boundary
 - `display.scale` : boundary scale for display
 - (many others) : many other arguments for design families and accrual parameters for survival

22

22

:

Basics: Operating Characteristics



- seqOC (
 - x : a seqDesign object
 - theta : alternatives for operating characteristics
 - how.many : used if theta and power not supplied
 - range.theta : used if theta and power not supplied
 - power : specification of theta via power
 - upper : indicator that upper power curve desired
 - lower : indicator that lower power curve desired
- Plotting functions
 - seqPlotASN (x, ...)
 - seqPlotPower (x, ...)
 - seqPlotStopProb (x, ...)

23

23

Additional Resources



- www.RCTdesign.org
 - SS Emerson, DL Gillen, JM Kittelson, GP Levin, SC Emerson
- Software
 - Documentation
 - Tutorials
 - Extensions (Bayesian evaluation; adaptive design evaluation)
- Learning
 - Short courses
 - Research talks
 - Case studies
- Methodology
 - Technical reports on a variety of RCT-related topics

24

24